search
Back to results

Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women

Primary Purpose

Osteoporosis, Osteopenia

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Genistein vs Risedronate
Sponsored by
Purdue University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Osteoporosis focused on measuring Bone Resorption, Phytoestrogens, Calcium, Genistein, Equol

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: At least 4 years post-menopausal Exclusion Criteria: Not currently taking estrogen replacement therapy or undergoing any treatment for osteoporosis Diagnosis of breast cancer Results of mammogram suggesting breast cancer

Sites / Locations

  • Purdue University

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Genistein vs. Risedronate

Genistein dose and source

Arm Description

Healthy post menopausal women who have been dosed with Ca41. Intervention, 100 mg Gensitein from soy protein isolate for 50 days. After a 50 day washout risedronate (Actonel- 5mg per day) for 50 days

Healthy post menopausal women will consume 5 products containing varying quantities of genistein from different sources for 50 days each in a randomized order. Each intervention period is separated by a 50 day washout period. Intervention: A) 50 mg genistein from soy protein isolate, B) 100 mg genistein from soy protein isolate, C)50 mg genistein from Novasoy, D) 100 mg genistein from Novasoy, E) 100 ng genistein from 50% Novasoy and 50% soy protein isolate

Outcomes

Primary Outcome Measures

Urinary markers of bone resorption; measured at the end of each treatment phase

Secondary Outcome Measures

Serum markers of bone resorption and calcium absorption; measured at the end of each treatment phase

Full Information

First Posted
October 25, 2005
Last Updated
May 3, 2018
Sponsor
Purdue University
Collaborators
National Center for Complementary and Integrative Health (NCCIH), Office of Dietary Supplements (ODS)
search

1. Study Identification

Unique Protocol Identification Number
NCT00244907
Brief Title
Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women
Official Title
Metabolism and Bone Health
Study Type
Interventional

2. Study Status

Record Verification Date
May 2018
Overall Recruitment Status
Completed
Study Start Date
January 2006 (undefined)
Primary Completion Date
May 2010 (Actual)
Study Completion Date
May 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Purdue University
Collaborators
National Center for Complementary and Integrative Health (NCCIH), Office of Dietary Supplements (ODS)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Estrogen is a hormone that helps prevent calcium loss and bone breakdown. During menopause, estrogen levels decrease. Insufficient amounts of estrogen may lead to bone loss and possibly osteoporosis. Isoflavones are natural compounds found in soy plants that may help provide protection against bone loss. This study will evaluate the effect of soy isoflavones on calcium absorption and bone loss in post menopausal women.
Detailed Description
Estrogen is a hormone that activates bone-forming cells and prevents calcium loss and bone breakdown. During menopause, estrogen levels decrease. Insufficient amounts of estrogen may accelerate bone breakdown and inhibit the body's ability to create new bone, thereby leading to bone loss and possibly osteoporosis. Various treatments have been developed to decrease bone loss in post-menopausal women. Actonel, for example, is an FDA-approved drug used to help prevent bone loss. Phytoestrogens are plant compounds with a structure similar to estrogen. They have also been shown to help reduce the negative effects of menopause. Isoflavones are a particular type of phytoestrogens that are found in soy plants and may act like estrogen in providing possible protection against bone loss. This study will compare the effects of isoflavones (including genistein, a type of isoflavone) versus Actonel on calcium absorption and bone loss in post-menopausal women. Participants in this double-blind cross-over study will first complete a screening process, which will include answering questions about their health habits, medical history, physical activity, and food patterns. They will then eat one soy bar daily for 3 days. On Day 4, a urine sample will be taken to assess their ability to metabolize phytoestrogen from soybeans. Participants will be randomly assigned to a specific treatment order. Participants will receive 1-4 unique soy isoflavones, followed by Actonel. Treatment phases will be separated by a 50-day washout period. All participants will also take calcium and vitamin D supplements throughout the study. Assessments will include bone density measurements, calcium absorption tests, and blood and urine tests. The study will last approximately 2.5 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoporosis, Osteopenia
Keywords
Bone Resorption, Phytoestrogens, Calcium, Genistein, Equol

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
23 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Genistein vs. Risedronate
Arm Type
Active Comparator
Arm Description
Healthy post menopausal women who have been dosed with Ca41. Intervention, 100 mg Gensitein from soy protein isolate for 50 days. After a 50 day washout risedronate (Actonel- 5mg per day) for 50 days
Arm Title
Genistein dose and source
Arm Type
Active Comparator
Arm Description
Healthy post menopausal women will consume 5 products containing varying quantities of genistein from different sources for 50 days each in a randomized order. Each intervention period is separated by a 50 day washout period. Intervention: A) 50 mg genistein from soy protein isolate, B) 100 mg genistein from soy protein isolate, C)50 mg genistein from Novasoy, D) 100 mg genistein from Novasoy, E) 100 ng genistein from 50% Novasoy and 50% soy protein isolate
Intervention Type
Dietary Supplement
Intervention Name(s)
Genistein vs Risedronate
Other Intervention Name(s)
Actonel
Intervention Description
Gensitein (100 gm) from soy protein isolate Risedronate (5 mg)
Primary Outcome Measure Information:
Title
Urinary markers of bone resorption; measured at the end of each treatment phase
Time Frame
Every 50 days
Secondary Outcome Measure Information:
Title
Serum markers of bone resorption and calcium absorption; measured at the end of each treatment phase
Time Frame
Every 50 days

10. Eligibility

Sex
Female
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: At least 4 years post-menopausal Exclusion Criteria: Not currently taking estrogen replacement therapy or undergoing any treatment for osteoporosis Diagnosis of breast cancer Results of mammogram suggesting breast cancer
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Connie M. Weaver, PhD
Organizational Affiliation
Purdue University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Purdue University
City
West Lafayette
State/Province
Indiana
ZIP/Postal Code
47907
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
15817872
Citation
Spence LA, Lipscomb ER, Cadogan J, Martin B, Wastney ME, Peacock M, Weaver CM. The effect of soy protein and soy isoflavones on calcium metabolism in postmenopausal women: a randomized crossover study. Am J Clin Nutr. 2005 Apr;81(4):916-22. doi: 10.1093/ajcn/81.4.916.
Results Reference
background
PubMed Identifier
19087429
Citation
Jackson GS, Weaver C, Elmore D. Use of accelerator mass spectrometry for studies in nutrition. Nutr Res Rev. 2001 Dec;14(2):317-34. doi: 10.1079/NRR200129.
Results Reference
background
PubMed Identifier
26245807
Citation
Pawlowski JW, Martin BR, McCabe GP, McCabe L, Jackson GS, Peacock M, Barnes S, Weaver CM. Impact of equol-producing capacity and soy-isoflavone profiles of supplements on bone calcium retention in postmenopausal women: a randomized crossover trial. Am J Clin Nutr. 2015 Sep;102(3):695-703. doi: 10.3945/ajcn.114.093906. Epub 2015 Aug 5.
Results Reference
derived
PubMed Identifier
25271941
Citation
Nakatsu CH, Armstrong A, Clavijo AP, Martin BR, Barnes S, Weaver CM. Fecal bacterial community changes associated with isoflavone metabolites in postmenopausal women after soy bar consumption. PLoS One. 2014 Oct 1;9(10):e108924. doi: 10.1371/journal.pone.0108924. eCollection 2014.
Results Reference
derived

Learn more about this trial

Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women

We'll reach out to this number within 24 hrs